Roisin Delaney's Research Focus
RAS is a critical oncogene in many cancers for which there is no effective therapy. Ras activates downstream effectors as part of a signaling nanocluster in association with other proteins. These may form surrogate targets for attacking KRas for therapy. Roisin Delaney will be researching the regulation of Ras signaling for cancer therapy. In specific, she will investigate the role of the signaling nanocluster PH domain protein CNKSRI in KRAS activity, how the PLEKHA7 PH protein interacts with CNKSRI to regulate KRAS activity and the role of PH domain binding agents as inhibitors of mutant KRAS signaling and cancer cell growth.